Multibagger Selection: Grok 4.7's picks
Grok 4.7 picked CAPR, INOD, NUVB, FEIM, PAYS with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Grok 4.7 |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | CAPR | — | 62% | — | — |
| 2 | INOD | — | 68% | — | — |
| 3 | NUVB | — | 65% | — | — |
| 4 | FEIM | — | 60% | — | — |
| 5 | PAYS | — | 58% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +1.26% | +1.80% | 1.27x | 0 |
The model's market view
Small- and mid-cap equities face mixed conditions in late 2026 amid selective risk appetite, with growth-oriented names showing dispersion. AI-related data services, commercial-stage oncology, and defense electronics exhibit operating inflections supported by backlog or launch ramps, while binary biotech events remain high-variance. Liquidity is adequate for the selected names, but valuation multiples compress easily on execution shortfalls.
Why each pick
CAPR
Capricor is a clinical-stage company advancing deramiocel, an allogeneic cell therapy for Duchenne muscular dystrophy. The stock has declined substantially from prior highs while cash remains sufficient for the near-term regulatory window. Approval or a clear path forward would represent a material commercial inflection for a company currently reporting limited or no product revenue.
INOD
Innodata provides data engineering, annotation, and evaluation services that support AI model training and agentic systems. Revenue has accelerated for multiple consecutive quarters with expanding adjusted gross margins, and the company has reiterated at least 40% full-year 2026 growth guidance. Free cash flow has turned strongly positive on a trailing basis.
NUVB
Nuvation Bio is commercializing IBTROZI (taletrectinib) for ROS1-positive NSCLC. Revenue has scaled rapidly post-launch, and the company holds a leading position in new patient starts. Cash reserves support continued commercialization while the safusidenib glioma program advances.
FEIM
Frequency Electronics designs precision timing and frequency products for space and defense. Q1 FY2027 revenue rose 70% year-over-year with gross margin recovering to 46% and a record $129 million funded backlog. Management targets at least $150 million revenue by FY2029.
PAYS
Paysign provides prepaid card programs and patient affordability solutions for pharmaceutical and plasma markets. Revenue grew 48% in Q2 2026, and management raised full-year 2026 revenue guidance to $114-117 million. The company is profitable with expanding margins.
Other models on the same run
| Model | Picks |
|---|---|
| Perplexity | ONDS, RCAT, AEVA, SOUN, RGTI |
| Gemini 3.6 Flash High | ONDS, RCAT, AEVA, SOUN, RGTI |
| Muse Spark 1.1 | LUNR, ACHR, SOUN, SMR, FLNC |
| Claude Sonnet 5.5 | AEHR, LUNR, SOUN, NNE, NVTS |
| GPT-6 | FLNC, BKSY, AMPX, INOD, ENVX |
| DeepSeek | AQST, CAPR, VNDA, CGEM, MLYS |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.